Description

The Smo Knockout NIH 3T3 Cell Line is a CRISPR/Cas9-edited knockout cell line designed to disrupt the Smo gene, which encodes Smoothened, the GPCR mediator of Hedgehog signaling. This cell line offers a defined loss-of-function background for dissecting Smo-dependent processes in mesenchymal fibroblasts. By eliminating functional Smo, researchers can interrogate pathway-specific responses with high reproducibility.

NIH 3T3 is an immortalized fibroblast line derived from Swiss mouse embryos, characterized by contact inhibition, stable growth, and high transfection efficiency. Its mesenchymal origin makes it a preferred model for studying signal transduction and developmental pathways. These features ensure robust performance in proliferation assays, pharmacological testing, and transfection-based manipulations, providing an optimal host for Smo knockout studies.

Smoothened (Smo) acts as the central transducer of the Hedgehog cascade. Under basal conditions, Patched1 (Ptch1) suppresses Smo; binding of Sonic Hedgehog (Shh) to Ptch1 lifts this inhibition, allowing Smo to localize to the primary cilium. Once there, Smo triggers Gli transcription factor activation by sequestering the negative regulator Sufu. This promotes transcription of target genes including Cyclin D1, Myc, and Bcl2. Smo activity is regulated by cholesterol and agonists like SAG, and is modulated by interacting proteins such as ??-arrestin 2, G??i, Kif7, GRK2, and CK1??. CRISPR-mediated disruption of Smo in this cell line abolishes Shh-induced Gli activation, creating a definitive loss-of-function model.

In the NIH 3T3 background, Smo knockout abolishes responsiveness to Shh, impairing Gli-driven transcription and proliferation. This renders the line an essential tool for evaluating Hedgehog pathway dependency and drug specificity. The model also enables exploration of non-canonical Smo functions and Ptch1-mediated effects independent of Smo, broadening investigations into Hedgehog network complexity.

Applications include Western blotting and RT-qPCR for Gli1/Ptch1 to confirm pathway inactivation, Gli-luciferase reporter assays, and immunofluorescence for ciliary localization. Cell proliferation (MTS) and vismodegib sensitivity assays assess functional outcomes. The line supports research in basal cell carcinoma, medulloblastoma, cancer biology, and drug discovery. For further details, please contact Ascent Research.